RVMDW — Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. Warrant (RVMDW) common stock listed on NASDAQ. It is led by Mark A. Goldsmith M.D., Ph.D., based in 700 Saginaw Drive, Redwood City, CA, United States, 94063, with about 883 employees. Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Net income was -$766.4M.

On the latest cached filing, RVMDW to acquire platform ($2.7M) (8-K 2026-09-01). Exhibit numbers: Deal $2.7M. Why it matters: Transaction value about $2.7M This RVMDW stock page is the analysis view: what changed in the numbers, and why it matters for Revolution Medicines, Inc. Warrant.

Use this RVMDW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RVMDW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RVMDW SEC filings page. Lician reads the product cache first so this HTML stays unique to Revolution Medicines, Inc. Warrant even when a live quote feed is slow.